The stock of NRX Pharmaceuticals Inc (NRXP) has seen a 8.29% increase in the past week, with a -20.07% drop in the past month, and a 94.21% flourish in the past quarter. The volatility ratio for the week is 10.17%, and the volatility levels for the past 30 days are at 9.96% for NRXP. The simple moving average for the past 20 days is 2.40% for NRXP’s stock, with a 8.15% simple moving average for the past 200 days.
Is It Worth Investing in NRX Pharmaceuticals Inc (NASDAQ: NRXP) Right Now?
Moreover, the 36-month beta value for NRXP is 1.39. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NRXP is 14.03M and currently, short sellers hold a 8.34% of that float. On March 17, 2025, NRXP’s average trading volume was 1.23M shares.
NRXP) stock’s latest price update
NRX Pharmaceuticals Inc (NASDAQ: NRXP)’s stock price has soared by 13.53 in relation to previous closing price of 2.07. Nevertheless, the company has seen a gain of 8.29% in its stock price over the last five trading days. prnewswire.com reported 2025-03-12 that – Conference call to take place at 8:30am ET – WILMINGTON, Del., March 12, 2025 /PRNewswire/ — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Monday, March 17, 2025 via press release, which will be available on the Company’s website at https://ir.nrxpharma.com/.
NRXP Trading at -20.80% from the 50-Day Moving Average
After a stumble in the market that brought NRXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.90% of loss for the given period.
Volatility was left at 9.96%, however, over the last 30 days, the volatility rate increased by 10.17%, as shares sank -20.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +53.59% upper at present.
During the last 5 trading sessions, NRXP rose by +8.29%, which changed the moving average for the period of 200-days by -40.51% in comparison to the 20-day moving average, which settled at $2.30. In addition, NRX Pharmaceuticals Inc saw 6.82% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NRXP starting from Javitt Jonathan C, who purchase 40,000 shares at the price of $1.17 back on Dec 17 ’24. After this action, Javitt Jonathan C now owns 84,634 shares of NRX Pharmaceuticals Inc, valued at $46,800 using the latest closing price.
Stock Fundamentals for NRXP
Current profitability levels for the company are sitting at:
- -2559.5 for the present operating margin
- 0.62 for the gross margin
The net margin for NRX Pharmaceuticals Inc stands at -2547.5. The total capital return value is set at 1.29.
Based on NRX Pharmaceuticals Inc (NRXP), the company’s capital structure generated -0.55 points at debt to capital in total, while cash flow to debt ratio is standing at -1.85. The debt to equity ratio resting at -0.35. The interest coverage ratio of the stock is -66.05.
Currently, EBITDA for the company is -18.5 million with net debt to EBITDA at -0.26. When we switch over and look at the enterprise to sales, we see a ratio of 5596.83. The receivables turnover for the company is 1.33for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.20.
Conclusion
To wrap up, the performance of NRX Pharmaceuticals Inc (NRXP) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
